In summary, our findings demonstrate that FADS1 inhibition effectively curtails renal cancer cell proliferation in vitro as well as tumor formation in vivo, primarily through the activation of the PERK-ATF4-ATF3 axis-mediated ER stress. Here, EIF2AK3 is linked to renal carcinoma.